Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04152499
Title Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (A264)
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Klus Pharma Inc.

pancreatic adenocarcinoma

urinary bladder cancer

triple-receptor negative breast cancer

gastric adenocarcinoma

ovary epithelial cancer



Age Groups: adult | senior
Covered Countries USA

No variant requirements are available.